|Day Low/High||95.67 / 96.41|
|52 Wk Low/High||64.55 / 102.70|
The largest impediment to success for firms like TLRY -- which is expected to report a 27 cent loss per share Tuesday night -- remains federal legalization of marijuana across the U.S.
Tilray will look to sustain a sanguine sentiment on cannabis stocks on Tuesday.
Sellers of the beverage company's shares have been acting more aggressively than buyers in recent weeks.
The catalyst for equities is now out of the bag, it is just a matter of finding companies with that catalyst before everyone catches on.
The tepid response shown to Wanda Sports Group is at odds with the strong performance of Chinese stock markets, suggesting U.S. listings are not the way for Chinese companies to go.
And as the semiconductor sector continues to shine, Brooks Automation is a name to keep in mind.
I'm only considering selling the puts. The dividend is not that attractive.
Courtesy of Wallethub - "We also eat a whole lot of hot dogs: 150 million in total. We make a toast or two to freedom and good old Uncle Sam, shelling out more than $1.6 billion on July Fourth beer and wine. And we travel, with nearly 47 million of ...
From lollipops to locomotives, Warren Buffett's has a full buffet of topics to address Saturday.
While the two tobacco giants have similar yields, both also have very different businesses, with different growth potential in the years ahead.
Investors can gain exposure to the high-flying cannabis industry without taking on undue risks.
Tilray will not be cash flow positive for another 2-3 years - that's not quick enough progress for me given its $7 billion dollar capitalization.
Pot stocks like Tilray have very ambitious valuations but the potential upside (in mergers and, fundamentally in food, drink, supplemental and medical applications) are undeniably immense. The view of a possible rapid rise in revenues and profits (a...
The move was helped by the TLRY's deals with AB InBev for beverages and Novartis for medical applications.
Fear-mongering over risk of BBB credits was immensely exaggerated and hurt many people's returns.
This is one report where the real driver will be what the company says and the tone they take when saying it.
Even with its 12% stock decline on Wednesday, Constellation Brands is more intriguing than it was yesterday.
In the interest of due diligence, we went and took a close look at the ground floor of the newest investment craze.
For the first time in years we don't have to sacrifice quality to maintain income.
Establishing who the stragglers are and what impact they might have in the future is the key at this point.
I'd be most interested in buying this name after a cap raise which I expect in the first quarter of 2019.
Perhaps no company has bought into the Canadian cannabis craze more than Constellation Brands.
The buy-in from other companies into the space has been far larger.
Tilray's technical history is limited, but a bullish divergence in a key chart could be foreshadowing a rally ahead.
Pot stock partnerships are a gateway to gains for cannabis investors.
Let's take a look at the charts.